Real-World Osilodrostat Effectiveness and Safety in Nonpituitary Cushing Syndrome
Antoine Tabarin(Université de Bordeaux), Nicolas Scheyer(Centre Hospitalier Régional et Universitaire de Nancy), Jérôme Bertherat(Centre National de la Recherche Scientifique), C. Vaillant(Centre Hospitalier du Mans), D. Drui(Centre Hospitalier Universitaire de Nantes), Bénédicte Decoudier(Centre Hospitalier Universitaire de Reims), Hervé Lefèbvre(Inserm), Nicolas Chevalier(Inserm), Frédéric Castinetti(Inserm), Arnd Mueller(Recordati (Italy)), Justine Cristante(Centre Hospitalier Universitaire de Grenoble), Wence Agbotounou(DBV Technologies (France)), Hélène Lasolle(Hospices Civils de Lyon), Sarah Fodil-Cherif(Centre Hospitalier Universitaire de Montpellier), Andrea Piacentini(Recordati (Italy)), J. Morera(Centre Hospitalier Universitaire de Caen Normandie), Mario Maldonado
Cited by 4
Related Papers
Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors
|European Journal of Endocrinology|2016|1.5k
Treatment of Acromegaly with the Growth Hormone–Receptor Antagonist Pegvisomant
|New England Journal of Medicine|2000|874
Combination Chemotherapy in Advanced Adrenocortical Carcinoma
|New England Journal of Medicine|2012|863
SDH Mutations Establish a Hypermethylator Phenotype in Paraganglioma
|Cancer Cell|2013|772
Human Health and Ocean Pollution
|Annals of Global Health|2020|751